IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Core Insights - IGC Pharma is expanding its AI-powered in-silico drug discovery platform to enhance the development of treatments for Alzheimer's disease [1] Company Developments - The company is integrating additional methodologies such as retrosynthetic analysis, molecular docking, toxicology and genotoxic assessments, and predictive bioactivity modeling [1] - This expansion aims to accelerate the identification and optimization of therapeutic candidates for Alzheimer's disease and related disorders [1]